Bliss GVS Pharma Ltd
NSE: BLISSGVS BSE: 506197
₹295.35
(1.83%)
Sat, 30 May 2026, 11:44 am
Market Cap29.95B
PE Ratio29.04
Dividend0.35
Health Technology
Pharmaceuticals: Major
24.5KBliss GVS Pharma Analysis
dividend
- Dividends per share have increased over the past 10 years.
- Dividends paid are thoroughly covered by earnings (10.3x coverage).
- Bliss GVS Pharma's pays a higher dividend yield than the bottom 25% of dividend payers in India (0.76%).
- Dividends per share have been volatile in the past 10 years (annual drop of over 20%).
- Bliss GVS Pharma's dividend is below the markets top 25% of dividend payers in India (3.08%).
health
- Bliss GVS Pharma is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
- Bliss GVS Pharma is profitable, therefore cash runway is not a concern.
- Bliss GVS Pharma is profitable, therefore cash runway is not a concern.
- Debt is well covered by operating cash flow (29%, greater than 20% of total debt).
- Debt is covered by short term assets, assets are 7.8x debt.
- Bliss GVS Pharma's cash and other short term assets cover its long term commitments.
- The level of debt compared to net worth has been reduced over the past 5 years (48.1% vs 12.9% today).
- Bliss GVS Pharma earns more interest than it pays, coverage of interest payments is not a concern.
- Bliss GVS Pharma's level of debt (12.9%) compared to net worth is satisfactory (less than 40%).
- High level of physical assets or inventory.
management
- The average tenure for the Bliss GVS Pharma board of directors is over 10 years, this suggests they are a seasoned and experienced board.
- Shibroor's compensation has been consistent with company performance over the past year, both up more than 20%.
- The tenure for the Bliss GVS Pharma management team is about average.
- Shibroor's remuneration is higher than average for companies of similar size in India.
misc
- Bliss GVS Pharma is not covered by any analysts.
past
- Bliss GVS Pharma's 1-year earnings growth exceeds its 5-year average (71.3% vs 9.8%)
- Bliss GVS Pharma's year on year earnings growth rate has been positive over the past 5 years.
- Bliss GVS Pharma used its assets more efficiently than the IN Pharmaceuticals industry average last year based on Return on Assets.
- Bliss GVS Pharma's earnings growth has exceeded the IN Pharmaceuticals industry average in the past year (71.3% vs 22.7%).
- Bliss GVS Pharma's use of capital deteriorated last year versus 3 years ago (Return on Capital Employed).
- Bliss GVS Pharma has not efficiently used shareholders’ funds last year (Return on Equity less than 20%).
value
- Bliss GVS Pharma is good value based on assets compared to the IN Pharmaceuticals industry average.
- Bliss GVS Pharma is good value based on earnings compared to the IN Pharmaceuticals industry average.
- Bliss GVS Pharma is good value based on earnings compared to the India market.
- BSE:506197 is up 8% outperforming the Pharmaceuticals industry which returned 6.8% over the past month.
- BSE:506197 is up 8% along with the India market (8%) over the past month.
- Bliss GVS Pharma's share price is above the future cash flow value, it's not available at a moderate discount (< 20%).
- Bliss GVS Pharma's share price is above the future cash flow value, it's not available at a substantial discount (< 40%).
- 506197 underperformed the Pharmaceuticals industry which returned 26.7% over the past year.
- 506197 underperformed the Market in India which returned -14.5% over the past year.